Willowbrook, IL (13 April, 2020) /EMPR.com – Centhaquine: An investigational resuscitative agent that is expected to provide hemodynamic stability, improve tissue oxygenation, reduce pulmonary edema, reduce acute respiratory distress syndrome, reduce multiple organ dysfunction score and decrease mortality in patients with COVID-19. Pharmazz is approaching various regulatory agencies regarding use of centhaquine as an adjunct in the management of critically ill patients with COVID-19; the drug has already been assessed in a phase 3 study for hypovolemic shock.

For the full article, visit: www.empr.com/home/news/drugs-in-the-pipeline/pipeline-investigational-therapies-for-covid-19/

For information about Centhaquine, visit: www.pharmazz.com